Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
-
601por Nagai, Kazuyuki, Doi, Ryuichiro, Katagiri, Fumihiko, Ito, Tatsuo, Kida, Atsushi, Koizumi, Masayuki, Masui, Toshihiko, Kawaguchi, Yoshiya, Tomita, Kenji, Oishi, Shinya, Fujii, Nobutaka, Uemoto, Shinji“…CONCLUSION: Strong expression of metastin and GPR54 by pancreatic cancer is associated with longer survival. Metastin expression is an independent prognostic factor for the survival of pancreatic cancer patients. …”
Publicado 2009
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
602por Leask, Andrew“…The matricellular protein CCN2 (connective tissue growth factor, CTGF) has been previously implicated in tumorigenesis. In pancreatic cancer cells, CCN2 expression occurs downstream of ras/MEK/ERK. …”
Publicado 2009
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
603“…Pancreatic cancer has proven to be chemo-resistant, with gemcitabine being the only cytotoxic agent approved for advanced pancreatic cancer since 1996. …”
Enlace del recurso
Enlace del recurso
Texto -
604por Reddy, Deepthi M., Townsend, Courtney M., Kuo, Yong-Fang, Freeman, Jean L., Goodwin, James S., Riall, Taylor S.“…RESULTS: We identified 1,730 subjects who underwent pancreatectomy for pancreatic cancer. The in-hospital mortality was 7.5%. …”
Publicado 2009
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
605“…BACKGROUND: Pancreatic cancer has a high mortality rate because it is usually diagnosed when metastasis have already occurred (microscopic and gross disease). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
606por Scharpf, Robert B., Iacobuzio-Donahue, Christine A., Cope, Leslie, Ruczinski, Ingo, Garrett-Mayer, Elizabeth, Lakkur, Sindhu, Campagna, Domenico, Parmigiani, Giovanni“…Using this approach, we identify several transcripts from the integrative analysis whose over-or under-expression in pancreatic cancer cell lines was validated by qPCR.…”
Publicado 2010
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
607“…The complex of symptoms in pancreatic cancer is vague, which often delays presentation and diagnosis. …”
Enlace del recurso
Enlace del recurso
Texto -
608“…We also discuss current evidence on the indications for these procedures in patients with unresectable pancreatic cancer.…”
Enlace del recurso
Enlace del recurso
Texto -
609por Campbell, Peter J, Yachida, Shinichi, Mudie, Laura J, Stephens, Philip J, Pleasance, Erin D, Stebbings, Lucy A, Morsberger, Laura A, Latimer, Calli, McLaren, Stuart, Lin, Meng-Lay, McBride, David J, Varela, Ignacio, Nik-Zainal, Serena A, Leroy, Catherine, Jia, Mingming, Menzies, Andrew, Butler, Adam P, Teague, Jon W, Griffin, Constance A, Burton, John, Swerdlow, Harold, Quail, Michael A, Stratton, Michael R, Iacobuzio-Donahue, Christine, Futreal, P Andrew“…Pancreatic cancer is an aggressive malignancy with 5-year mortality of 97–98%, usually due to widespread metastatic disease. …”
Publicado 2010
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
610por Kwei, Kevin A., Shain, A. Hunter, Bair, Ryan, Montgomery, Kelli, Karikari, Collins A., van de Rijn, Matt, Hidalgo, Manuel, Maitra, Anirban, Bashyam, Murali D., Pollack, Jonathan R.“…Pancreatic cancer is a deadly disease, and new therapeutic targets are urgently needed. …”
Publicado 2011
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
611por Sullivan, Jennifer, Gong, Qiaoke, Hyslop, Terry, Lavu, Harish, Chipitsyna, Galina, Yeo, Charles J., Arafat, Hwyda A.“…MCP-1 is a promising biomarker in pancreatic cancer. The potential of using MCP-1 to distinguish PDA from IPMN patients must be studied in larger populations to validate and demonstrate its eventual clinical utility.…”
Publicado 2011
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
612por Haridas, Dhanya, Chakraborty, Subhankar, Ponnusamy, Moorthy P., Lakshmanan, Imayavaramban, Rachagani, Satyanarayana, Cruz, Eric, Kumar, Sushil, Das, Srustidhar, Lele, Subodh M., Anderson, Judy M., Wittel, Uwe A., Hollingsworth, Michael A., Batra, Surinder K.“…While MUC16 is well known as a biomarker in ovarian cancer, its expression pattern in pancreatic cancer (PC), the fourth leading cause of cancer related deaths in the United States, remains unknown. …”
Publicado 2011
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
613“…Pancreatic cancer has one of the worst prognoses among all types of cancers. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
614“…Despite the well-described interactions of cancer cells with several stromal components, i.e., inflammatory cells, cancer-associated fibroblasts, endothelial cells, and pericytes, the investigation of their peculiar relationship with neural cells is still at its first footsteps. Pancreatic cancer (PCa) with its abundant stroma represents one of the best-studied examples of a malignant tumor with a mutually trophic interaction between cancer cells and the intratumoral nerves embedded in the desmoplastic stroma. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
615por Habermehl, Daniel, Kessel, Kerstin, Welzel, Thomas, Hof, Holger, Abdollahi, Amir, Bergmann, Frank, Rieken, Stefan, Weitz, Jürgen, Werner, Jens, Schirmacher, Peter, Büchler, Markus W, Debus, Jürgen, Combs, Stephanie E“…INTRODUCTION: To evaluate efficacy and secondary resectability in patients with locally advanced pancreatic cancer (LAPC) treated with neoadjuvant chemoradiotherapy (CRT). …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
616
-
617por Collins, Meredith A., Brisset, Jean-Christophe, Zhang, Yaqing, Bednar, Filip, Pierre, Josette, Heist, Kevin A., Galbán, Craig J., Galbán, Stefanie, di Magliano, Marina Pasca“…Pancreatic cancer is one of the deadliest human malignancies, and its prognosis has not improved over the past 40 years. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
618“…Development of systemic treatment for advanced pancreatic cancer (APC) has been challenging. After fluorouracil, gemcitabine (GEM) became the treatment of choice based on its benefit of symptom relief. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
619“…In our research we demonstrated that among many factors influencing tumor microenvironment c-Met receptor, infiltrating macrophages and MMP2 have significant influence on development and invasion of pancreatic cancer.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
620por Tactacan, Carole M, Chang, David K, Cowley, Mark J, Humphrey, Emily S, Wu, Jianmin, Gill, Anthony J, Chou, Angela, Nones, Katia, Grimmond, Sean M, Sutherland, Robert L, Biankin, Andrew V, Daly, Roger J“…BACKGROUND: The receptor tyrosine kinase RON exhibits increased expression during pancreatic cancer progression and promotes migration, invasion and gemcitabine resistance of pancreatic cancer cells in experimental models. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto